z-logo
Premium
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Author(s) -
Kantarjian Hagop,
O'Brien Susan,
Ravandi Farhad,
Cortes Jorge,
Shan Jianqin,
Bennett John M.,
List Alan,
Fenaux Pierre,
Sanz Guillermo,
Issa JeanPierre,
Freireich Emil J.,
GarciaManero Guillermo
Publication year - 2008
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.23697
Subject(s) - medicine , international prognostic scoring system , leukocytosis , chronic myelomonocytic leukemia , myelodysplastic syndromes , multivariate analysis , anemia , oncology , bone marrow
BACKGROUND. Recent studies have highlighted issues with the International Prognostic Scoring System (IPSS) model in relation to the exclusion of many subgroups that now represent a large proportion of patients with myelodysplastic syndrome (MDS) (eg, secondary MDS, chronic myelomonocytic leukemia [CMML] with leukocytosis, prior therapy) and its lack of applicability to most patients on investigational programs, because many would have received prior therapies and would have had MDS for a significant length of time. METHODS. The authors analyzed 1915 patients with MDS who were referred from 1993 to 2005 (including those with CMML, secondary MDS, and MDS with prior therapy). Only 507 patients (26%) had primary MDS without prior therapy (ie, classifiable by the IPSS). Patients were divided randomly into a study group (n = 958) and a test group (n = 957). RESULTS. A multivariate analysis of prognostic factors in the study group identified the following adverse, independent factors as continuous and categoric values ( P <.001): poor performance, older age, thrombocytopenia, anemia, increased bone marrow blasts, leukocytosis, chromosome 7 or complex (≥3) abnormalities, and prior transfusions. Cutoffs for anemia, thrombocytopenia and blasts, and cytogenetic subsets were different according to the IPSS. The new MDS prognostic model divided patients into 4 prognostic groups with significantly different outcomes. The model was validated in the test group. Applying the prognostic score of the new model within the 4 IPSS risk groups, overall, and in patients who had primary MDS without prior therapy was found to be highly prognostic in each subset. Applying the IPSS within each of the 4 risk groups of the new MDS model was not found to be prognostic. CONCLUSIONS. The new model accounts for duration of MDS and prior therapy. It is applicable to any patient with MDS at any time during the course of MDS. Cancer 2008. © 2008 American Cancer Society.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here